

## REFERENCES

- Adhikari, D., Roy, T.B., Biswas, A., Chakraborty, M.L., Bhattacharya, B., Maitra, T.K., Basu, A.K. & Chandra, S. (1995) Efficacy and safety of oral iron chelating agent deferiprone in beta-thalassemia and hemoglobin E-beta thalassemia. *Indian Pediatr*, **32**, 855-861.
- Ahmed, N.K., Hanna, M. & Wang, W. (1986) Nontransferrin-bound serum iron in thalassemia and sickle cell patients. *Int J Biochem*, **18**, 953-956.
- al-Refai, F.N., Wickens, D.G., Wonke, B., Kontoghiorghes, G.J. & Hoffbrand, A.V. (1992) Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. *Br J Haematol*, **82**, 431-436.
- Amer, J., Goldfarb, A. & Fibach, E. (2003) Flow cytometric measurement of reactive oxygen species production by normal and thalassaemic red blood cells. *Eur. J. Haematol*, **70**, 84-90.
- Ammon, H.P. & Wahl, M.A. (1991) Pharmacology of Curcuma longa. *Planta Med*, **57**, 1-7.
- Anderson, B.F., H.M., B., Norris, G.E., Rice, D.W. & EN, B. (1989) Crytallographic structure analysis and refinement. *J. Mol Biol*, **209**, 711-734.
- Andrews, N. (1999) Disorder of Iron Metabolism. *The New England Journal of Medicine*, **341**, 1986-1995.
- Araujo, C.C. & Leon, L.L. (2001) Biological activities of Curcuma longa L. *Mem Inst Oswaldo Cruz*, **96**, 723-728.
- Askwith, C., Eide, D., Van, H., Bernard, P.S., Lil, D.S. & Kalplan, J. (1994) The FET3 gene of *S. cerevisiae* encodes a multicopper oxidase required for ferrous iron uptake. *Cell*, **76**, 403-410.
- Baker, E.N. & Lindley, P.F. (1992) New perspectives on the structure and function of transferrin. *J inorg Biochem*, **47**, 147-160.
- Bartlett, A.N., Hoffbrand, A.V. & Kontoghiorghes, G.J. (1990) Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations. *Br J Haematol*, **76**, 301-304.
- Becker, W., Reece, J. & Poenie, M. (1996) The Regulation of Gene Expression. *The World of the Cell*. 3rd edition, California, 632-633.
- Bergamini, C.M., Gambetti, S., Dondi, A. & Cervellati, C. (2004) Oxygen, reactive oxygen species and tissue damage. *Curr Pharm Des*, **10**, 1611-1626.

- Beutler, E., Felitti, V., Gelbart, T. & Ho, N. (2001) Genetics of iron storage and hemochromatosis. *Drug Metab Dispos*, **29**, 495-499.
- Bezkorovainy, A. (1989) Biochemistry of nonheme iron in man. I. Iron proteins and cellular iron metabolism. *Clin Physiol Biochem*, **7**, 1-17.
- Bichile, S.K., Mehta, P.J. & Parekh, S.J. (1993) Toxicity of oral iron chelator L1. *J Assoc Physicians India*, **41**, 323-324.
- Boran, M., Dalva, I., Yazicioglu, A., Akbay, E. & Cetin, S. (1993) Correction of anaemia in haemodialysis patients with recombinant human erythropoietin. *Int Urol Nephrol*, **25**, 197-203.
- Breuer, W., Hershko, C. & Cabantchik, Z.I. (2000) The importance of non-transferrin bound iron in disorders of iron metabolism. *Transfus Sci*, **23**, 185-192.
- Brock, J.H. (1989) Iron-binding proteins. *Acta Paediatr Scand Suppl*, **361**, 31-43.
- Burrows, L. (1995) Peritoneal dialysis technician: a process for role definition. *Anna J*, **22**, 319-322.
- Canaud, B., Cristol, J., Morena, M., Leray-Moragues, H., Bosc, J. & Vaussenat, F. (1999) Imbalance of oxidants and antioxidants in haemodialysis patients. *Blood Purif*, **17**, 99-106.
- Cheung, A.K. (1994) Quantitation of dialysis. The importance of membrane and middle molecules. *Blood Purif*, **12**, 42-53.
- Chua, A., Ingram, H., Raymond, K. & Baker, E. (2003) Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells. *Eur. J. Biochem*, **270**, 1689-1698.
- Conney, A.H., Lysz, T. & Ferrano, T. (1991) Inhibitory effects of curcumin and some related dietary compounds on tumor promotion and arachidonic acid metabolism in mouse skin. *Adv. Enzyme Regul*, **31**, 385-389.
- Crichton, R.R. & Charlotheaux-Wauters, M. (1987) Iron transport and storage. *Eur J Biochem*, **164**, 485-506.
- Crowley, J.P., Nealey, T.A., Metzger, J., Pono, L. & Chazan, J.A. (1987) Transfusion and long-term hemodialysis. *Arch Intern Med*, **147**, 1925-1928.
- Danielski, M., Ikizler, T.A., McMonagle, E., Kane, J.C., Pupim, L., Morrow, J. & Himmelfarb, J. (2003) Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. *Am J Kidney Dis*, **42**, 286-294.

- de Valk, B., Addicks, M.A., Gosriwatana, I., Lu, S., Hider, R.C. & Marx, J.J. (2000) Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. *Eur J Clin Invest*, **30**, 248-251.
- Diav-Citrin, O. & Koren, G. (1997) Oral iron chelation with deferiprone. *Pediatr Clin North Am*, **44**, 235-247.
- Durken, M., Nielsen, P., Knobel, S., Finckh, B., Hermming, C., Dresow, B., Kohlschutter, B., Stockschlader, M., Kruger, W.H., Kohlschutter, A. & Zander, A.R. (1997) Nontransferrin-bound iron in serum of patients receiving bone marrow transplants. *Free Radic Biol Med*, **22**, 1159-1163.
- Eschbach, J.W. & Adamson, J.W. (1999) Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. *Kidney Int Suppl*, **69**, S35-43.
- Eschbach, J.W., Varma, A. & Stivelman, J.C. (2002) Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia? *Nephrol Dial Transplant*, **17 Suppl 5**, 2-7.
- Esposito, B.P., Breuer, W., Slotki, I. & Cabantchik, Z.I. (2002) Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. *Eur J Clin Invest*, **32 Suppl 1**, 42-49.
- Fairbanks, V.F. & Klee, G.G. (1987) Biochemical aspects of hematology. In : *Fundamentals of Clinical Chemistry*, 3rd edition, Tietz NW. W.B.Saunders Company, Philadelphia.
- Feder, J.N., Gnirke, A., Thomas, W. & Tsuchihashi, Z. (1996) A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. *Nat. Genet*, **13**, 399-408.
- Finch, C.A. & Huebers, H.A. (1986) Iron metabolism. *Clin Physiol Biochem*, **4**, 5-10.
- Flemming, M.D., Romano, M.A., Su, M.A., Garrick, M.D. & Andrew, N.C. (1998) Microcytic anemia mice have a mutation in Nramp 2, a candidate iron transporter gene. *Proc. Natl Acad. Sci. USA*, **95**, 1148-1153.
- Flemming, M.D., Trenor, C.C., Andrew, N.C. & Dietrich, W.F. (1997) Microcytic anemia mice have a mutation in Nramp 2, a candidate iron transporter gene. *Nat. Genet*, **16**, 383-386.
- Griffiths, W.J., Kelly, A.L. & Cox, T.M. (1999) Inherited disorder of iron storage and transport. *Mol. Med. Today*, **5**, 43143-43148.

- Gross, C.N., Irrinki, A., Feder, J.N. & Enn, C.A. (1998) Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the transferrin receptor implies a role in intracellular iron regulation. *J. Biol. Chem*, **273**, 22068-22074.
- Gunshin, H., Mackenzie, B., Berger, U.V., Gunshin, Y. & Hediger, M.A. (1997) Cloning and characterization of a mammalian proton-coupled metal-ion transporter. *Nature*, **388**, 482-488.
- Gutteridge, J.M. (1981) Thiobarbituric acid-reactivity following iron-dependent free-radical damage to amino acids and carbohydrates. *FEBS Lett*, **128**, 343-346.
- Harrison, P.M. & Arosio, P. (1996) Ferritin: Molecular properties, iron storage function and cellular regulation. *Biochim Biophys Acta*, **1275**, 161-203.
- Hentze, M.W. & L.C., K. (1996) Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide and oxidative stress. *Proc. Natl Acad. Sci. USA*, **93**, 8175-8182.
- Hershkko, C., Graham, G., Bates, G.W. & Rachmilewitz, E.A. (1978) Non-specific serum iron in thalassemia; an abnormal serum fraction of potential toxicity. *Br. J. Haematol*, **40**, 255-263.
- Hider, R.C. (2002) Nature of non-transferrin bound iron. *Eur. J. Clin. Invest*, **32**, 50-55.
- Hill, L.L. (1990) Body composition, normal electrolyte concentrations, and the maintenance of normal volume, tonicity, and acid-base metabolism. *Pediatr Clin North Am*, **37**, 241-256.
- Hoffbrand, A.V., F, A.L.-R., Davis, B., Siritanakul, N., Jackson, B.F., Cochrane, J., Prescott, E. & Wonke, B. (1998) Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. *Blood*, **91**, 295-300.
- Howard, D.H. (1999) Acquisition, transport, and storage of iron by pathogenic fungi. *Clin Microbiol Rev*, **12**, 394-404.
- Huang, M.T., Deschner, E.E., Newmark, H.L., Wang, Z.Y., Ferraro, T.A. & Conney, A.H. (1992) Effect of dietary curcumin and ascorbyl palmitate on azoxymethanol-induced colonic epithelial cell proliferation and focal areas of dysplasia. *Cancer Lett*, **64**, 117-121.

- Huang, M.T., Lou, Y.R., Ma, W., Newmark, H.L., Ruhl, K. & Conney, H. (1994) Inhibitory effects of dietary curcumin on forestomach, duodenal and colon carcinogenesis in mice. *Cancer Res.*, **54**, 5841-5847.
- Huang, M.T., Lysz, T., Ferraro, T., Abidi, T.F., Laskin, J.D. & Conney, A.H. (1991) Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. *Cancer Res.*, **51**, 813-819.
- Huang, M.T., Ma, W., Yen, P., Xie, J.G., J., H., Fenkel, K. & Conney, H. (1997) Inhibitory effects of topical application of low doses of curcumin on TPA-induced tumor promotion and oxidized DNA bases in mouse epidermis. *Carcinogenesis*, **518**, 83-88.
- Huang, M.T., Smart, R.C., Wong, C.Q. & Conney, A.H. (1988) Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. *Cancer Res.*, **48**, 5941-5946.
- Hughes, R.T., Smith, T., Hesp, R., Hulme, B., Dukes, D.C., Bending, M.B., Pearson, J., Raja, K.B., Cotes, P.M. & Pippard, M.J. (1992) Regulation of iron absorption in iron loaded subjects with end stage renal disease: effects of treatment with recombinant human erythropoietin and reduction of iron stores. *Br J Haematol*, **82**, 445-454.
- ICSH (1978) Recommendations for measurement of serum iron in human blood. . *Br. J. Haematol*, **28**, 281-294.
- Iwakami, S., Shibuya, M. & Tseng, C.F. (1986) Inhibition of arachidonate 5-lipoxygenase by phenolic compounds. *Chem Pharm Bull*, **34**, 3960-3963.
- Kalantar-Zadeh, K., Ikizler, T.A., Block, G., Avram, M.M. & Kopple, J.D. (2003) Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. *Am J Kidney Dis*, **42**, 864-881.
- Keyer, K. & Imlay, J.A. (1997) Inactivation of dehydratase [4Fe-4S] clusters and disruption of iron homeostasis upon cell exposure to peroxynitrite. *J Biol Chem*, **272**, 27652-27659.
- Kiuchi, F., Shibuya, M. & Sankawa, U. (1982) Inhibitors of prostaglandin biosynthesis from *Alpinia officinarum*. *Chem Pharm Bull*, **30**, 2279-2282.

- Kolb, G., Nolting, C., Eckle, I., Muller, T., Lange, H. & Havemann, K. (1991) The role of membrane contact in hemodialysis-induced granulocyte activation. *Nephron*, **57**, 64-68.
- Kontoghiorghes, G.J. (1990) Design, properties, and effective use of the oral chelator L1 and other alpha-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia. *Ann N Y Acad Sci*, **612**, 339-350.
- Kunchandy, E. & Rao, M.N.A. (1990) Oxygen radical scavenging activity of curcumin. *Int'l. J. Pharm*, **38**, 239-240.
- Lebron, J.A., Bennett, M.J., Vaughn, D.E. & Chirino, A.J. (1998) Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. *Cell*, **93**, 111-123.
- Lee, D.H. & Jacobs, D.R., Jr. (2004) Serum markers of stored body iron are not appropriate markers of health effects of iron: a focus on serum ferritin. *Med Hypotheses*, **62**, 442-445.
- Lieu, P.T., Heiskala, M., Peterson, P.A. & Yang, Y. (2001) The roles of iron in health and disease. *Mol Aspects Med*, **22**, 1-87.
- Lim, P.S., Wei, Y.H. & Y, Y.L. (1999) Enhanced oxidative stress in hemodialysis patients receiving intravenous iron therapy. *Nephrol dial transplant*, **14**, 2680-2687.
- Macro, B., Erika, F., Romano, G. & Monica, S. (2002) Curcuminoids as potential new iron-chelating agents: polarographic and potentiometric study on their Fe(III) complexing ability. *Inorganica Chimica Acta*, **328**, 61-68.
- Maiz, H.B., Abderrahim, E. & Zouaghi, K. (2002) Anemia and end-stage renal disease in the developing world. *Artif Organs*, **26**, 760-764.
- Malliaraki, N., Mpliamplias, D., Kampa, M., Perakis, K., Margioris, A.N. & Castanas, E. (2003) Total and corrected antioxidant capacity in hemodialyzed patients. *BMC Nephrol*, **4**, 4.
- Mancuso, C., Bonsignore, A., Di Stasio, E., Mordente, A. & Motterlini, R. (2003) Bilirubin and S-nitrosothiols interaction: evidence for a possible role of bilirubin as a scavenger of nitric oxide. *Biochem Pharmacol*, **66**, 2355-2363.
- Masuda, T., Hidaka, K., Shinohara, A., Maekawa, T., Takeda, Y. & Yamaguchi, H. (1999) Chemical studies on antioxidant mechanism of curcuminoid: analysis of radical reaction products from curcumin. *J Agric Food Chem*, **47**, 71-77.

- Mckie, A.T. (1999) A novel IRE-containing mRNA predominantly expressed in duodenum and placenta encodes a baso-lateral membrane protein associated with iron transport. *Proc. World Congress Iron Metabolism Sorento, Italy, 23-28 May.*, **21**, 195-199.
- Miquel, J., Bernd, A., Sempere, J.M., Diaz-Alperi, J. & Ramirez, A. (2002) The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. *Arch Gerontol Geriatr*, **34**, 37-46.
- Morgan, E.H. (1981) Transferrin, biochemistry, physiology and clinical significance. *Mol Aspects Med*, **4**, 1-123.
- Morgan, E.H. & Oates, P.S. (2002) Mechanisms and regulation of intestinal iron absorption. *Blood Cells Mol Dis*, **29**, 384-399.
- Mukhopadhyay, C.K., Attieh, Z.K. & Fox, P.L. (1998) Role of ceruloplasmin in cellular iron uptake. *Science*, **279**, 714-717.
- Muller-Wiefel, D.E., Lenhard, V. & Scharer, K. (1981) Body iron stores in children with chronic renal failure in relation to HLA phenotypes. *Proc Eur Dial Transplant Assoc*, **18**, 524-530.
- Nomura, S., Osawa, G. & Karai, M. (1990) Treatment of a patient with end-stage renal disease, severe iron overload and ascites by weekly phlebotomy combined with recombinant human erythropoietin. *Nephron*, **55**, 210-213.
- Odani, H., Shinzato, T., Matsumoto, Y., Usami, J. & Maeda, K. (1999) Increase in three alpha,beta-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. *Biochem Biophys Res Commun*, **256**, 89-93.
- Olivieri, N.F., Matsui, D., Liu, P.P., Blendis, L., Cameron, R., McClelland, R.A., Templeton, D.M. & Koren, G. (1993) Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients. *Bone Marrow Transplant*, **12 Suppl 1**, 9-11.
- Patro, B.S., Rele, S., Chintalwar, G.J., Chattopadhyay, S., Adhikari, S. & Mukherjee, T. (2002) Protective activities of some phenolic 1,3-diketones against lipid peroxidation: possible involvement of the 1,3-diketone moiety. *Chembiochem*, **3**, 364-370.
- Peter, H.H. (1983) [Iron chelation. Biological significance and medical application]. *Schweiz Med Wochenschr*, **113**, 1428-1433.

- Pippard, M.J. (1994) Secondary iron overload. In: Brock J.H., Halliday J.W., Pippard M.J., Powell L.W. (eds) *Iron metabolism in health and Disease*. Sauder, London. 272-309.
- Pippard, M.J. & Weatherall, D.J. (2000) Deferiprone for thalassaemia. *Lancet*, **356**, 1444-1445.
- Ponka, P. (1997) Tissue-specific regulation of iron metabolisms in erythroid cells. *Blood*, **89**, 1-25.
- Ponka, P., Beaumont, C. & Richardson, D.R. (1998) Function and regulation of transferrin and ferritin. *Semin Hematol*, **35**, 35-54.
- Porter, J.B., Abeysinghe, R.D., Marshall, L., Hider, R.C. & Singh, S. (1996) Kinetics of removal and reappearance of non-transferrin-bound plasma iron with desferrioxamine therapy. *Blood*, **88**, 705-714.
- Quereda, C., Teruel, J.L., Lamas, S., Marcen, R., Matesanz, R. & Ortuno, J. (1987) HLA antigens and serum ferritin in hemodialysis patients. *Nephron*, **45**, 104-110.
- Rao, C.V., Rivenson, A., Simi, B. & Reddy, B.S. (1995) Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. *Cancer Res*, **55**, 259-266.
- Ravindranath, V. & Chandrasekhara, N. (1981) In vitro studies on the intestinal absorption of curcumin in rats. *Toxicology*, **20**, 251-257.
- Richardson, D.R. & Ponka, P. (1997) The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. *Biochim Biophys Acta*, **1331**, 1-40.
- Riedel, H.D., Remus, A.J., Fitscher, B.A. & Stremmel, W. (1995) Characterization and partial purification of a ferrireductase from human duodenal microvillous membrane. *Biochem. J.*, **309**, 745-748.
- Rock, R.C., Walker, W.G. & Jennings, C.D. (1987) Nitrogen metabolites and renal function. *Fundamentals of Clinical Chemistry*. 3rd edition, Philadelphia, 669-704.
- Roy, C.N., Penny, D.M., Feder, J.N. & Enn, C.A. (1999) The hereditary hemochromatosis protein, HFE specifically regulates transferrin-mediated iron uptake in HeLa cells. *J. Biol. Chem*, **274**, 9022-9028.
- Sadrzadeh, S.M., Hallaway, P.E. & Nanji, A.A. (1997) The long-acting parenteral iron chelator, hydroxyethyl starch-deferoxamine, fails to protect against alcohol-induced liver injury in rats. *J Pharmacol Exp Ther*, **280**, 1038-1042.

- Seifert, A., von Herrath, D. & Schaefer, K. (1987) Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. *Q J Med*, **65**, 1015-1024.
- Singh, S., Hider, R.C. & Porter, J.B. (1990) A direct method for quantification of non-transferrin-bound iron. *Anal. Biochem*, **186**, 320-323.
- Sorenson, J.R. (2002) Cu, Fe, Mn, and Zn chelates offer a medicinal chemistry approach to overcoming radiation injury. *Curr Med Chem*, **9**, 639-662.
- Sreejayan & Rao, M.N. (1994) Curcuminoids as potent inhibitors of lipid peroxidation. *J Pharm Pharmacol*, **46**, 1013-1016.
- Stobie, S., Tyberg, J., Matsui, D., Fernandes, D., Klein, J., Olivieri, N., Bentur, Y. & Koren, G. (1993) Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients. *Int J Clin Pharmacol Ther Toxicol*, **31**, 602-605.
- Subramanian, M., Sreejayan, Rao, M.N., Devasagayam, T.P. & Singh, B.B. (1994) Diminution of singlet oxygen-induced DNA damage by curcumin and related antioxidants. *Mutat Res*, **311**, 249-255.
- Sui, Z., Salto, R., Li, J., Craik, C. & Ortiz, P.R. (1993) Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. *Bailliere's Clin. Haematol*, **1**, 415-422.
- Tamg, D.C., Huang, T.P., Chen, T.W. & Yang, W.C. (1999) Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. *Kidney Int Suppl*, **69**, S107-118.
- Thielen, V., Close, P. & Hennen, G. (2004) [Hemochromatosis: the most common of rare diseases]. *Rev Med Liege*, **59**, 149-154.
- Turnbull, A. (1978) Iron absorption. In *Iron in biochemistry and medicine*, Academic Press, New York.
- Van Wyck, D.B. (1989) Iron management during recombinant human erythropoietin therapy. *Am J Kidney Dis*, **14**, 9-13.
- Vaziri, N.D., Ni, Z., Oveisi, F., Liang, K. & Pandian, R. (2002) Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. *Hypertension*, **39**, 135-141.

- Vulpe, C., Kuo, Y.M., Murphy, T.L., Cowley, L. & Anderson, G.J. (1999) Hephhaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. *Nat Genet*, **21**, 195-199.
- Waring, W.S., Convery, A., Mishra, V., Shenkin, A., Webb, D.J. & Maxwell, S.R. (2003) Uric acid reduces exercise-induced oxidative stress in healthy adults. *Clin Sci (Lond)*, **105**, 425-430.
- Wauters, J.P. (1995) Biocompatibility aspects of chronic hemodialysis and their clinical relevance. *Clin Nephrol*, **44 Suppl 1**, S19-23.
- Wingard, R.L., Parker, R.A., Ismail, N. & Hakim, R.M. (1995) Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. *Am J Kidney Dis*, **25**, 433-439.
- Wright, P.A. (1995) Nitrogen excretion: three end products, many physiological roles. *J Exp Biol*, **198** ( Pt 2), 273-281.
- Zehnder, C. & Blumberg, A. (1989) Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis. *Clin Nephrol*, **31**, 55-59.
- Zupan, I.P., Varl, J., Kovac, D., Cernelc, P., Mlakar, U., Andoljsek, D., Pretnar, J., Zver, S. & Modic, M. (2001) Indices of iron status in patients treated by chronic haemodialysis. *Pflugers Arch*, **442**, R202-203.